"Cancer"

There are many ways to treat prostate cancer and radiation therapy is a common treatment for prostate cancer, but many prostate cancer patients want to know what the side effects of radiation therapy are.

Everyone wants to be in good health because we all know that good health is the only way to live a better life. However, many diseases still occur frequently nowadays, so we need to know about the common diseases

Memorial Sloan Kettering Cancer Center is the world's oldest and largest private cancer centre. for more than 130 years, the centre has been committed to excellence in patient care, innovative research and top-notch medical education programs

Preoperative oxaliplatin-fluoropyrimidine chemotherapy given to colon cancer patients did not increase the risk of perioperative complications in colon cancer patients and did reduce postoperative recurrence rates, according to the results of the international phase 3/4 FOxTROT trial.

The cause of lupus erythematosus is not known, but research suggests that it is related to genes, ultraviolet light, drugs, infection and oestrogen.

MD Anderson Cancer Center, founded in 1941, is a world-renowned oncology hospital located in Houston, Texas, USA, and was one of the three early comprehensive cancer treatment centres designated by the National Cancer Initiative in 1971. It is one of the first three comprehensive cancer treatment centres designated by the National Cancer Initiative in 1971, and one of 39 comprehensive cancer treatment centres designated by the Medical Oncology Society, and is recognised as a good cancer hospital.

Blood cancer is a very complicated disease and should be treated in a timely manner to improve your disease and health condition and to gradually relieve your symptoms.

UniversityClinic Hamburg-Eppendorf, UKE was founded on 17 May 1889 in Hamburg, Germany's second largest city, and is one of Europe's leading hospitals and the NO.1 medical centre of its size in Hamburg.

The results of a new study show that Ubamatamab, a bispecific antibody drug, has shown excellent results and a good safety profile in patients with ovarian cancer.

Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.